Ablative Solutions, Inc., was founded in 2011 with a vision to address the significant unmet clinical need of systemic hypertension.

Ablative Solutions is certified to ISO 13485, a comprehensive quality management system standard for medical device manufacturers.

Leadership Team

David Fischell, PhD – Acting COO and Chairman of the BOD

Dr. David Fischell is a serial entrepreneur who has founded 14 biomedical device companies in the last 20 years, including Angel Medical Systems, that has developed an implantable heart attack detection and patient alerting system, eNeura, Inc (2002) Transcranial Magnetic Stimulation systems for Migraine Headaches; NeuroPace, Inc. (1997) implantable brain pacemakers to treat epilepsy and Ablative Solutions (2011) to develop chemical based renal denervation catheters to treat hypertension.  He currently has 156 issued U.S. patents, mostly medical devices, and from 1998 through 2003 was the primary designer of coronary stents, including the BX Velocity™ and Cypher™ Stents for Cordis now implanted in more than 7 million patients.


Tim Fischell, MD, FACC – Chief Executive Officer & Chief Medical Officer

A practicing interventional cardiologist, prolific inventor and entrepreneur, Dr. Fischell is currently Professor of Medicine at Michigan State and Medical Director of the Borgess Heart Institute Department of Cardiovascular Research and the Interventional Cardiology Fellowship Program. An inventor and co-inventor on over 70 patented devices, he co-designed the stent upon which the J&J drug-eluting stent platform is based. Co-founder of several biomedical start-up companies (Angel Medical Systems, Svelte, Ostial Solutions, etc.), his honors include the Thorax Center Andreas Gruentzig Award for Inventor of the Year in 1997. Dr. Fischell has presented over 200 papers and authored more than 110 articles in peer-reviewed journals and 20 book chapters.

TIm Fischell

Nicole Haratani, RN, BSN – VP Global Clinical, Quality and Regulatory Affairs

Nicole’s extensive background includes clinical and regulatory expertise in medical device and combination products. Prior to Ablative Solutions, Inc., she was Vice President of Clinical Affairs at Guided Delivery Systems. She held director or senior director positions with Boston Scientific, Sadra Medical, and the Cardiovascular Research Foundation. Her clinical affairs experience includes Abbott Vascular, Guidant, and St. Jude Medical. She has co-authored numerous scientific papers and presented at multiple medical device conferences. Nicole has a background of nursing with experience in trauma, cardiac cath lab, and cardiac surgery ICU.


Darrin Kent – VP of Research & Development and Product Manufacturing

An experienced R&D leader, Darrin has 20 years of experience in the medical device industry designing and commercializing dozens of devices.   He has honed his management, engineering, pre-clinical research and manufacturing skills at REV·1 Engineering, a contract design and development firm. Prior to that, he developed innovative endovascular devices at Sequent Medical (later Terumo) and Guidant Vascular Intervention (later Abbott Vascular). Darrin has a BSE from Cal Poly, SLO and he is a named inventor on 30 US patents, granted or pending.

Darrin Kent

Michaun Auzenne – VP Accounting and Finance

Michaun has over 20 years of diverse accounting and financial management experience with both private and public companies. Before joining Ablative Solutions, Michaun held management positions at KLA-Tencor, NetApp and most recently as Corporate Controller with Ancora Heart, Inc. (formerly Guided Delivery Systems, Inc.) In her current role with Ablative Solutions, Inc., her responsibilities include forecasting, financial analysis, cash management, human resources, financial reporting and fundraising.

Michaun Auzenne

Helen Parise, PhD – VP Biometrics

With over 20 years of experience in medical research and clinical trials, Helen Parise has collaborated on the design, implementation and analysis of global clinical studies and research driven investigations as a Research Assistant Professor at Boston University, Director of Biostatistics at Veristat, Inc., a CRO, and more recently as Director of Biometrics, Executive Director of the Clinical Trials Center and Chief Statistical Officer at the Cardiovascular Research Foundation and Columbia University School of Medicine. With a doctorate in Biostatistics from Harvard University School of Public Health, Hele n has over 100 collaborative publications and has given numerous talks on the nuances of cardiovascular device trials.


Board of Directors

David Fischell, PhD (Chairman)
CEO, Angel Medical Systems – Shrewsbury, NJ

Tim Fischell, MD, FACC 
Chief Executive Officer & Chief Medical Officer, Ablative Solutions – Fair Haven, NJ

Steven L. Almany, MD, FACC 
Corporate Vice Chief of Cardiology, William Beaumont Hospital – Royal Oak, MI

Paul Buckman
President & CEO, Conventus Orthopaedics. – Maple Grove, MN

Dale Grogan, CSCIP 
Managing Director, Michigan Accelerator Fund – Grand Rapids, MI 

Investor Relations

August 30, 2017–Ablative Solutions Announces Presentation at the Baird Global Healthcare Conference

September 13, 2016–FDA Allows Ablative Solutions to Initiate its Phase 2 TARGET-BP I Trial of Combination Drug/Device Therapy for Hypertension under its IND

May 16, 2016–Ablative Solutions Announces Presentations on Alcohol-Mediated Renal Denervation at the EuroPCR Congress 2016

March 26, 2016–Chemical renal denervation may be feasible approach to resistant hypertension

February 16, 2016–Ablative Solutions Announces First Two Patients Treated in the European Peregrine Post-Market Study for Renal Denervation

December 2, 2015–Ablative Solutions Adds Key Opinion Leader to its Scientific Advisory Board

May 13, 2015Ablative Solutions Announces CE Mark of the Peregrine System™ Infusion Catheter

October 14, 2014Ablative Solutions Treats the First Patient in the European CE-Mark Study for Renal Denervation

June 11, 2014Ablative Solutions Receives U.S. Patent for Peregrine System™ Infusion Catheter

May 6, 2014Ablative Solutions Strengthens Its Scientific Advisory Board

February 4, 2014Investors Express Confidence in Ablative Solutions’ Approach of PeriVascular Renal Denervation with a $9.5M Series B Financing



Fischell TA, Vega F, Raju N, Johnson ET, Kent DJ, Ragland RR, Fischell DR, Almany SL, Ghazarossian VE, Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model, EuroIntervention. 2013 May 20; 9(1):140-7.